By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Novo Nordisk chief Lars Fruergaard Jørgensen to step down
News

Novo Nordisk chief Lars Fruergaard Jørgensen to step down

News Room
Last updated: 2025/05/16 at 7:55 AM
By News Room
Share
4 Min Read
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast.

The Danish group that developed the Wegovy and Ozempic drugs said on Friday that it had started the search for a new boss after agreeing with Jørgensen that new leadership was needed.

“Considering the recent market challenges, the share price decline and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders,” Novo said.

Shares in the drugmaker have fallen more than 50 per cent in the past year, causing it to lose its crown as Europe’s largest listed company by market capitalisation.

Investors have become concerned that its obesity and diabetes drugs are losing market share to US rival Eli Lilly, and have been disappointed by trial results from next-generation medicines in its pipeline.

Last week, the company cut sales and profit forecasts for the year, blaming the rapid expansion of replica drugs in the US. These cheaper alternatives — sold by so-called compounding pharmacies — were temporarily allowed when there was a shortage of the drugs.

Novo said sales growth for this year was now expected to be 13 to 21 per cent at constant exchange rates, compared with earlier guidance of 16 to 24 per cent. It forecast operating profit growth of 16 to 24 per cent, compared with a previous range of 19 to 27 per cent.

Jørgensen has led the drugmaker for eight years, during which time the share price has tripled. 

In its statement on Friday, Novo noted concern about the company’s share price “since mid-2024”. Shares fell 21 per cent in one day in late December when the company announced that its follow-up obesity drug CagriSema had missed its target in a late-stage clinical trial.

Novo said it would make an announcement about its search for a new chief executive “in due course”. Jørgensen would continue in his role for a period to ensure a smooth transition, it added.

The Novo Nordisk Foundation, which owns the company through Novo Holdings, is increasing its representation on the board. Lars Rebien Sørensen, the foundation’s chair, will begin to participate in board meetings immediately.

Jørgensen said he was “proud of the results” he had produced at the company along with colleagues “who work every day to drive change to defeat serious chronic diseases”.  

Shares in Novo Nordisk fell following the announcement, trading 3.8 per cent lower on the day.

Read the full article here

News Room May 16, 2025 May 16, 2025
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Meta’s Scale AI deal, Adobe earnings, Microsoft’s record high: Analyst weighs in

Watch full video on YouTube

Why Even High Earners Are Living Paycheck To Paycheck

Watch full video on YouTube

Empire State Realty Trust, Inc. (ESRT) Q2 2025 Earnings Call Transcript

Empire State Realty Trust, Inc. (NYSE:ESRT) Q2 2025 Earnings Conference Call July…

Stocks slide as Middle East tensions rise, energy shares gain, crypto portfolio tips

Watch full video on YouTube

Why 3D printed houses are on the rise

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

News

Empire State Realty Trust, Inc. (ESRT) Q2 2025 Earnings Call Transcript

By News Room
News

Crown Castle Inc. 2025 Q2 – Results – Earnings Call Presentation (NYSE:CCI)

By News Room
News

Microsoft poaches top Google DeepMind staff in AI talent war

By News Room
News

White Brook Capital Partners Q2 2025 Commentary

By News Room
News

EU must strengthen Asian security ties despite US pressure, says Kaja Kallas

By News Room
News

US embassy in China warns exit bans risk straining bilateral relations

By News Room
News

Client Challenge

By News Room
News

Donald Trump’s escalating attacks on Federal Reserve unnerve investors

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?